{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T02:40:08Z","timestamp":1744425608044,"version":"3.40.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"am","delay-in-days":336,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jiac-j.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jiac.2025.102668","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:17:35Z","timestamp":1740615455000},"page":"102668","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative study of ensitrelvir and symptomatic therapy in healthcare workers with mild COVID-19: A single center retrospective analysis in Chiba, Japan"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9184-7175","authenticated-orcid":false,"given":"Jun","family":"Hirai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4606-7150","authenticated-orcid":false,"given":"Yuki","family":"Hanai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2025.102668_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2174\/0113892029291098240129113500","article-title":"COVID-19: recent insight in genomic feature, pathogenesis, immunological biomarkers, treatment options and clinical updates on SARS-CoV-2","volume":"25","author":"Deshmukh","year":"2024","journal-title":"Curr Genom"},{"key":"10.1016\/j.jiac.2025.102668_bib2","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/s41467-024-44973-1","article-title":"Risk of SARS-CoV-2 reinfection during multiple Omicron variant waves in the UK general population","volume":"15","author":"Wei","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jiac.2025.102668_bib3","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3390\/v16050757","article-title":"COVID-19 variants and vaccine development","volume":"16","author":"Zhao","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.jiac.2025.102668_bib4","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00119-23","article-title":"COVID-19 therapeutics","volume":"37","author":"Focosi","year":"2024","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jiac.2025.102668_bib5","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.cmi.2024.04.012","article-title":"An update on the anti-spike monoclonal antibody pipeline for SARS-CoV-2","volume":"30","author":"Focosi","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiac.2025.102668_bib6","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s40121-024-00976-5","article-title":"Molnupiravir use among patients with COVID-19 in real-world settings: a systematic literature review","volume":"13","author":"Richmond DiBello","year":"2024","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jiac.2025.102668_bib7","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/acem.14896","article-title":"Paxlovid for nonhospitalized patients with COVID-19","volume":"31","author":"Johari","year":"2024","journal-title":"Acad Emerg Med"},{"key":"10.1016\/j.jiac.2025.102668_bib8","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00632-22","article-title":"Safety, tolerability, and pharmacokinetics of the novel antiviral agent ensitrelvir fumaric acid, a SARS-CoV-2 3CL protease inhibitor, in healthy adults","volume":"66","author":"Shimizu","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2025.102668_bib9","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1093\/jac\/dkac257","article-title":"Efficacy of ensitrelvir against SARS-CoV-2 in a delayed-treatment mouse model","volume":"77","author":"Nobori","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2025.102668_bib10","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s40265-024-02039-y","article-title":"Ensitrelvir fumaric acid: first approval","volume":"84","author":"Syed","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.jiac.2025.102668_bib11","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.bbrc.2023.01.040","article-title":"Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally","volume":"645","author":"Kawashima","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jiac.2025.102668_bib12","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/cid\/ciac933","article-title":"Efficacy and safety of ensitrelvir in patients with mild-to-moderate Coronavirus disease 2019: the phase 2b part of a randomized, placebo-controlled, phase 2\/3 study","volume":"76","author":"Mukae","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102668_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00697-22","article-title":"A randomized phase 2\/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: results of the phase 2a part","volume":"66","author":"Mukae","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2025.102668_bib14","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jiac.2020.09.027","article-title":"Comparative evaluation of nasopharyngeal swab and saliva specimens for the molecular detection of SARS-CoV-2 RNA in Japanese patients with COVID-19","volume":"27","author":"Sakanashi","year":"2021","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2025.102668_bib15","doi-asserted-by":"crossref","first-page":"304","DOI":"10.7883\/yoken.JJID.2020.061","article-title":"Development of genetic diagnostic methods for detection for novel Coronavirus 2019(nCoV-2019) in Japan","volume":"73","author":"Shirato","year":"2020","journal-title":"Jpn J Infect Dis"},{"key":"10.1016\/j.jiac.2025.102668_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/v15091952","volume":"15","author":"Hirai","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.jiac.2025.102668_bib17","doi-asserted-by":"crossref","first-page":"e860","DOI":"10.1093\/cid\/ciaa1616","article-title":"Repeated Coronavirus disease 2019 molecular testing: correlation of severe acute respiratory syndrome Coronavirus 2 culture with molecular assays and cycle thresholds","volume":"73","author":"Gniazdowski","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2025.102668_bib18","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.3390\/v12121420","article-title":"Comparison of rapid antigen tests for COVID-19","volume":"12","author":"Yamayoshi","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.jiac.2025.102668_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2024.107265","article-title":"Impact of early antiviral therapy on SARS-CoV-2 clearance time in high-risk COVID-19 subjects: a propensity score matching study","volume":"149","author":"Colaneri","year":"2024","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jiac.2025.102668_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ph16050721","article-title":"Molnupiravir, Nirmatrelvir\/Ritonavir, or Sotrovimab for high-risk COVID-19 patients infected by the Omicron variant: hospitalization, mortality, and time until negative swab test in real life","volume":"16","author":"Cegolon","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jiac.2025.102668_bib21","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13095","article-title":"The effect of nirmatrelvir-ritonavir on viral clearance and length of hospital stay in patients infected with SARS-CoV-2 omicron variants","volume":"17","author":"Wang","year":"2023","journal-title":"Influenza Other Respi Viruses"},{"key":"10.1016\/j.jiac.2025.102668_bib22","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1007\/s40121-024-01046-6","article-title":"Modeling the impact of ensitrelvir on SARS-CoV-2 dynamics and its application for assessment of transmission mitigation of patients with COVID-19","volume":"13","author":"Yamaguchi","year":"2024","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jiac.2025.102668_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmni.2024.101522","article-title":"Real world effectiveness of early ensitrelvir treatment in patients with SARS-CoV-2, a retrospective case series","volume":"62","author":"Abe","year":"2024","journal-title":"New Microbes New Infect"},{"key":"10.1016\/j.jiac.2025.102668_bib24","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jiac.2024.02.015","article-title":"Ensitrelvir in patients with SARS-CoV-2: a retrospective chart review","volume":"30","author":"Yamato","year":"2024","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2025.102668_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.54991","article-title":"Efficacy and safety of 5-day oral ensitrelvir for patients with mild to moderate COVID-19: the SCORPIO-SR randomized clinical trial: the SCORPIO-SR randomized clinical trial","volume":"7","author":"Yotsuyanagi","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jiac.2025.102668_bib26","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000039080","article-title":"Treatment with ensitrelvir for COVID-19 in hospitalized patients of very advanced age: case series","volume":"103","author":"Tomita","year":"2024","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.jiac.2025.102668_bib27","article-title":"Real-world efficacy of ensitrelvir in hospitalized patients with COVID-19 in Japan: a retrospective observational study","volume":"16","author":"Yoshida","year":"2024","journal-title":"Cureus"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25000650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25000650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T02:16:43Z","timestamp":1744424203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X25000650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1341321X25000650"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102668","relation":{},"ISSN":["1341-321X"],"issn-type":[{"type":"print","value":"1341-321X"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative study of ensitrelvir and symptomatic therapy in healthcare workers with mild COVID-19: A single center retrospective analysis in Chiba, Japan","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102668","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102668"}}